Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1213/ANE.0000000000002629 | DOI Listing |
J Med Internet Res
January 2025
Center for Community-Engaged Artificial Intelligence, School of Science & Engineering, Tulane University, New Orleans, LA, United States.
There is a critical need for community engagement in the process of adopting artificial intelligence (AI) technologies in public health. Public health practitioners and researchers have historically innovated in areas like vaccination and sanitation but have been slower in adopting emerging technologies such as generative AI. However, with increasingly complex funding, programming, and research requirements, the field now faces a pivotal moment to enhance its agility and responsiveness to evolving health challenges.
View Article and Find Full Text PDFEnviron Sci Process Impacts
January 2025
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.
: several adverse effects of ozone (O) and nitrogen dioxide (NO) are assessed using combined oxidant capacity (O) and redox-weighted oxidant capacity (Owtx) as surrogates. However, the associations of oxidant capacity (O and Owtx) with platelet-based inflammatory indicators and the potential modifying role of physical activity (PA) remain unclear. : 31 318 participants were selected from the baseline survey of the Henan Rural Cohort Study.
View Article and Find Full Text PDFImmunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggests almost one third of myeloma patients acquire mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, having clearly explicable effects on cereblon function.
View Article and Find Full Text PDFIn patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen prior to autologous transplant is the standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). Here, we report safety and efficacy outcomes of six 28-day cycles of IsaKRD.
View Article and Find Full Text PDFBlood
January 2025
Hospital Santa Creu i Sant Pau, Barcelona, Spain.
CD30-directed CART cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the non-soluble part of CD30, and the manufacturing process includes a modulation of ex vivo T cell activation, as well as the addition of interleukin-21 to IL-7 and IL-15 to promote stemness of T cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!